Aeroexina Masilinus: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 19: | Line 19: | ||
| '''Type of Vaccine''' || [[wikipedia:RNA Vaccine|mRNA]] | | '''Type of Vaccine''' || [[wikipedia:RNA Vaccine|mRNA]] | ||
|- | |- | ||
| '''Booster Required''' || | | '''Booster Required''' || Yes (2 Weeks After) | ||
|- | |- | ||
| '''Cost''' || K/30 | | '''Cost''' || K/30 | ||
|- | |- | ||
|} | |} | ||
Revision as of 16:00, 18 February 2021
 | This article is incomplete because it is pending further input from participants, or it is a work-in-progress by one author. Please comment on this article's talk page to share your input, comments and questions. Note: To contribute to this article, you may need to seek help from the author(s) of this page. |
| Aeroexina Masilinus | |
| |
| Target Pathogen | Influenza A Virus |
| Type | Vaccine |
| Company | BioLabs |
| Date First Used | January 17, 2021 |
| Type of Vaccine | mRNA |
| Booster Required | Yes (2 Weeks After) |
| Cost | K/30 |